A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocy

clinical trial

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocy is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT04285567

P6099clinical trial phasephase III clinical trialQ42824827
P17countrySpainQ29
ItalyQ38
United States of AmericaQ30
AustraliaQ408
P582end time2023-04-08
P1050medical conditionleukemiaQ29496
P2899minimum age18
P1132number of participants165
P4844research interventionfludarabine phosphateQ185916
bendamustine hydrochlorideQ27272066
obinutuzumabQ389496
(RS)-cyclophosphamideQ408524
rituximabQ412323
vidarabineQ415107
venetoclaxQ23671272
P1813short nameCRISTALLO
P859sponsorHoffmann-La RocheQ212646
P580start time2020-02-28
P8363study typeinterventional studyQ78089383
P1476titleA Prospective, Open-Label, Multicenter Randomized Phase III Study to Compare The Efficacy and Safety of A Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/Bendamustine and Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL(17P) or TP53 Mutation